125 Fortune Boulevard
About Nitto Avecia
Nitto BioPharma, Inc., is a clinical stage biopharmaceutical company located in San Diego focused on the discovery and development of novel RNA-based therapeutics for intractable diseases. Clinical assets include a liver fibrosis program (BMS-986263/ND-L02-s0201), partnered with BMS and in Phase 2 in the US, an Idiopathic Pulmonary Fibrosis program (ND-L02-s0201) in Phase 2 in the US and Europe and Oncology program (NBF-006) in Phase 1 in the US . Nitto BioPharma is also advancing several programs for intractable diseases including Oncology and fibrosis.
14 articles with Nitto Avecia
Nitto Denko Avecia Inc. announced today that Detlef Rethage will step down from the position of President of Nitto Denko Avecia Inc., effective July 16, 2018.
Avecia announced today the opening of a new corporate office in Cambridge, MA, to support its operations and corporate development activities, and to be more accessible to clients.
Nitto Denko Avecia Inc. Acquires The Businesses Of Irvine Pharmaceutical Services, Inc. & Avrio Biopharmaceuticals
Avecia Biotechnology Inc. Has Engaged BioTechLogic as Consultants to Assist in Expanding Its Quality Management System (QMS) and in Preparing for Post Approval Manufacturing
Avecia Biotechnology Inc. Launches pAVEway(TM) - Advanced Protein Expression for the Manufacture of Biopharmaceuticals
Avecia Biotechnology Inc. And TriLink Partner To Offer Seamless Scale-Up In Oligonucleotide Manufacturing